Potential value of autoantibodies as biomarkers of chronic graft-versus-host disease after allogeneic stem cell transplantation

We investigated the value of autoantibodies as biomarkers of chronic graft-versus-host disease (cGVHD) by analyzing the autoantibody profiles of 65 patients (34 cGVHD and 31 non-cGVHD) surviving longer than three months after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Autoantibo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Zhejiang University. B. Science 2019-10, Vol.20 (10), p.849-860
Main Authors: Hao, Bing, Gao, Song, Sang, Yi-wen, Wang, Lin, Meng, Xue-qin, You, Jing-ya
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antibodies
Antibodies, Antinuclear - blood
Antigens
Antinuclear antibodies
Autoantibodies
Autoantibodies - blood
Biomarkers
Biomarkers - blood
Biomedical and Life Sciences
Biomedicine
Chronic Disease
Female
Graft vs Host Disease - blood
Graft vs Host Disease - diagnosis
Graft-versus-host reaction
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic Stem Cell Transplantation - mortality
Hematopoietic stem cells
Humans
Immunofluorescence
Male
Middle Aged
Nucleoli
Recurrence
Stem cell transplantation
Stem cells
Transplantation
Transplantation, Homologous
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated the value of autoantibodies as biomarkers of chronic graft-versus-host disease (cGVHD) by analyzing the autoantibody profiles of 65 patients (34 cGVHD and 31 non-cGVHD) surviving longer than three months after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Autoantibodies to at least one antigen were detected in 45 patients (70.8%), with multiple autoantibodies detected in 30 patients (46.2%). Antinuclear antibodies (ANAs) were the most frequently detected autoantibodies, with a significantly higher prevalence in non-cGVHD patients and cGVHD patients than that in healthy controls (HCs). ANA-nucleolar (ANA-N) was the main immunofluorescence pattern of ANA-positivity in both the non-cGVHD and cGVHD groups. There was a higher prevalence of anti-Ro52-positivity in non-cGVHD and cGVHD patients than in HC. Liver cGVHD was significantly associated with anti-Ro52-positivity. However, cGVHD activity and severity were not associated with the presence of autoantibodies. Similarly, there were no significant differences in overall survival or relapse among the four groups of patients expressing autoantibodies. Our results suggest that autoantibodies have limited value in predicting cGVHD.
ISSN:1673-1581
1862-1783
DOI:10.1631/jzus.B1900205